Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 5, 1998, Pages 370-376

  Behnia, Kamelia ^a,b   Boroujerdi, Mehdi ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adriamycin; Enterohepatic recirculation

Indexed keywords

ADRIAMYCINONE; DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROHEPATIC CIRCULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BILE; CATHETERIZATION; DOXORUBICIN; ENTEROHEPATIC CIRCULATION; MALE; MODELS, BIOLOGICAL; RATS;

EID: 0031905298     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050753     Document Type: Article

References (14)

1. Powis G (1991) Toxicity of free radical forming anticancer agents. Powis G, Hacker M In: The toxicity of anticancer drugs. Pergamon Press, p. 113
2. Leandro J, Dyck J, Poppe D, Shore R, Airhart C, Greenberg M, Gilday D, Smallhorn J, Benson L (1994) Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 74(11): 1152
3. Aviles A, Arevila N, Diaz Maqueo JC, Gomez T, Garcia R, Nambo MJ (1993) Late cardiotoxic toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 11(3-4): 275
4. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E (1979) Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 63: 827
5. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross over study. Cancer Chemother Pharmacol 21: 221
6. Speth P, Linssen PCM, Boezman JBM (1987) Cellular and plasma Adriamycin concentrations in long term infusion therapy of leukemic patients. Cancer Chemother Pharmacol 20: 305
7. Robert J (1987) Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration? Cancer Drug Deliv 4(3): 191
8. Robert J, Vrignaud P, Nguyen-Ngoc T, Llisia A, Mauriac L, Hurteloup P (1985) Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 69(6): 633
9. Carlo MC, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. Cancer Chemother Pharmacol 21: 221
10. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53: 555
11. Bouma J, Bejinen JH, Bult A, Underberg WM (1986) Anthracycline antitumor agents: a review of physico-chemical and analytical properties as well as stability. Pharm Wedblad 8: 109
12. Cusack BJ, Young SP, Driskell J, Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in rabbit. Cancer Chemother Pharmacol 32: 53
13. 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study. Cancer Chemother Pharmacol 12: 157
14. Tavaloni N, Guarino MA (1980) Biliary and urinary excretion of Adriamycin in anesthetized rats. Pharmacology 20: 256